首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4791篇
  免费   69篇
  国内免费   73篇
电工技术   28篇
综合类   52篇
化学工业   83篇
金属工艺   20篇
机械仪表   43篇
建筑科学   51篇
矿业工程   13篇
能源动力   2篇
轻工业   97篇
水利工程   15篇
石油天然气   49篇
武器工业   6篇
无线电   76篇
一般工业技术   49篇
冶金工业   4223篇
原子能技术   1篇
自动化技术   125篇
  2024年   4篇
  2023年   7篇
  2022年   10篇
  2021年   22篇
  2020年   15篇
  2019年   12篇
  2018年   24篇
  2017年   21篇
  2016年   18篇
  2015年   26篇
  2014年   28篇
  2013年   34篇
  2012年   46篇
  2011年   53篇
  2010年   46篇
  2009年   47篇
  2008年   46篇
  2007年   41篇
  2006年   46篇
  2005年   46篇
  2004年   25篇
  2003年   24篇
  2002年   13篇
  2001年   12篇
  2000年   12篇
  1999年   142篇
  1998年   1377篇
  1997年   731篇
  1996年   465篇
  1995年   263篇
  1994年   221篇
  1993年   257篇
  1992年   40篇
  1991年   52篇
  1990年   62篇
  1989年   51篇
  1988年   56篇
  1987年   60篇
  1986年   47篇
  1985年   57篇
  1983年   5篇
  1982年   17篇
  1981年   24篇
  1980年   26篇
  1979年   3篇
  1978年   7篇
  1977年   82篇
  1976年   196篇
  1975年   4篇
  1955年   3篇
排序方式: 共有4933条查询结果,搜索用时 22 毫秒
991.
The aim of this study was to determine the effect of a short-term ethinyl estradiol/levonorgestrel medication on blood flow in the uterine arteries in postmenopausal women in a prospective placebo-controlled double-blind study. Twenty-one healthy postmenopausal woman at least 2 years after menopause received 60 micrograms ethinyl estradiol (EE) for 14 days followed by 40 micrograms EE plus 125 micrograms levonorgestrel (LNG) for 12 days (total treatment period 26 days). Sonographically, uterine volume, endometrial thickness, and blood flow in the uterine arteries [as reflected by pulsatility (PI) and resistance indices (RI)] were measured. Uterine size increased from 44 to 80 mL (day 14, p < 0.001) and 87 mL (day 26, p = NS). Endometrium grew from 3 to 8 mm (day 14, p < 0.001) and 11 mm (day 26, p = NS). Uterine arterial PI fell from 2.76 to 1.37 (day 14, p < 0.001) and 1.34 (day 26, p = NS), whereas RI fell from 0.9 to 0.68 (day 14 and day 26, p < 0.001). In conclusion, short-term treatment with LNG does not antagonize the vascular effect of EE on the uterine arteries as reflected by PI and RI. This result might have clinical significance in the selection of the progestin used in hormonal replacement therapy.  相似文献   
992.
AIM: To evaluate sub-Tenon's anaesthesia as an alternative to peribulbar anaesthesia. METHODS: 109 consecutive patients listed for various eye operations (including cataract, trabeculectomy, and vitrectomy) under peribulbar anaesthesia were operated on under sub-Tenon's anaesthesia instead. After topical anaesthesia a buttonhole was fashioned through the conjunctiva and Tenon's capsule 10 mm posterior to the limbus. 1.5 ml of lignocaine 2% was then delivered to the posterior sub-Tenon's space using a blunt cannula. The surgical procedure was performed immediately after the completion of the anaesthetic procedure. Chemosis, conjunctival haemorrhage, degree of akinesia, and pain scoring were analysed. RESULTS: There were no anaesthesia related complications. The administration of the block was painless for 99.1% of the patients. In all, 97.3% reported no pain during surgery. There was no akinesia when assessed just after the completion of the block and akinesia was limited when assessed after surgery. Chemosis and conjunctival haemorrhage were frequent but caused no intraoperative problems. CONCLUSION: Sub-Tenon's anaesthesia is an efficient and safe anaesthetic technique. It is a good alternative to peribulbar anaesthesia.  相似文献   
993.
Two cardiology X-ray rooms were monitored with dose-area product meters as part of a Regional Patient Dosimetry Programme. Dose-area product measurements on over 2000 patients undergoing examinations in the cardiology rooms are presented. The data have been corrected according to patient size where possible. In room A mean dose-area product values for coronary angiography, coronary angioplasty, radiofrequency ablation and mitral valvuloplasty were found to be 47.7, 72.2, 91.1 and 161.9 Gy cm2 respectively. In room B mean dose-area product values for coronary angiography and coronary angioplasty were found to be 23.4 and 51.6 Gy cm2 respectively. Observational studies were used to deduce the typical projections and technique factors. This typical examination was used to simulate an angiogram from which it was possible to derive factors to convert measured dose-area product values into estimates of effective dose. In room A, the effective doses were estimated to be 9.4, 14.2, 17.3 and 29.3 mSv for coronary angiography, coronary angioplasty, radiofrequency ablation and mitral valvuloplasty, respectively. The effective doses during coronary angiography and coronary angioplasty, performed in room B, were found to be 4.6 and 10.2 mSv, respectively. A regional survey of the frequency of these cardiac procedures was performed. It was deduced that the annual collective effective dose from these cardiac procedures in the North of England, the former Northern Region, was 45.7 manSv.  相似文献   
994.
Murine Leydig (TM3) and Sertoli (TM4) cell lines were studied as nonprofessional antigen-presenting cells using the antigen model of human choriogonadotropin (hCG alpha/beta) and specific T-cell hybridomas. Both cell lines were treated with IFN-gamma to induce I-A(d) and I-E(d) molecules expression. Only the TM3 cell line, which expressed MHC-class II molecules upon IFN-gamma stimulation, was able to uptake, process, and present the human choriogonadotropin beta subunit to related T-cell hybridomas. Interestingly, the TM3 cell line was incapable of presenting the human choriogonadotropin alpha subunit, the presentation of which, by classical APC, is highly efficient. Using T-cell hybridomas directed against the immunogenic regions of hCG alpha/beta previously described in BALB/c mice, we showed that the TM3 cell line generated a narrower peptide repertoire than classical APC (i.e., B cells, macrophages, and dendritic cells). This experimental system suggests that Leydig cells could initiate, in vivo, an autoimmune process directed against gonadal tissues. In particular, such a mechanism has been evoked in experimental autoimmune orchitis.  相似文献   
995.
研究了稀土离子与NaY分子筛滤饼柱的交换过程。结果表明,与间歇交换相比,采用分子筛滤饼柱进行稀土离子交换,可以在较短时间内得到较高的稀土离子交换度。调整稀土离子和NH4^ 在交换液中的比例,可以在滤饼柱上获得具有一定稀土离子交换度且稀土分布均匀的Y型分子筛产品。交换液温度对稀土与NH4^ 混合交换的稀土交换度影响较大,但可以通过调整稀土离子与NH4^ 在交换液中的比例弥补交换度的差异。用约3倍于分子筛量的去离子水以洗去分子筛上残余的Na^ 、稀土离子和Cl^-。  相似文献   
996.
997.
BACKGROUND: Previous studies suggest differences in the fixation disparity curves obtained with the Sheedy Disparometer and the Wesson Fixation Disparity Card, the two most commonly used methods for measuring fixation disparity. In one study the investigators proposed that the differences do not exist for subgroups divided by phoria. The purpose of this paper is to try to clarify this issue by use of two large sets of data. METHODS: Dissociated phorias were measured by the von Graefe method. Fixation disparity curves were plotted using the Disparometer and the Wesson card. RESULTS: Type I fixation disparity curves were most common with the Wesson card. Type II curves were found more often with the Disparometer than with the Wesson card. The x-intercepts were shifted in the base-in (BI) direction with the Wesson card compared to the Disparometer. The y-intercepts were shifted in the exo direction with the Wesson card compared to the Disparometer. The differences were statistically significant regardless of whether the dissociated phoria was exo or eso. The slope of the fixation disparity curve was steeper with the Wesson card than with the Disparometer. The difference was statistically significant for exophores but not for esophores. The differences between results obtained with the two instruments are not consistent from one subject to another as shown by high standard deviations of the differences. CONCLUSIONS: The fixation disparity curves measured with these two instruments are different. Fixation disparity parameters obtained from one of these instruments cannot be used with normative findings from the other.  相似文献   
998.
999.
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号